Phase 1 Multiple Myeloma in Relapse Clinical Trials
11 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–11 of 11 trials
Recruiting
Phase 1
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma in Relapse
Kelonia Therapeutics, Inc.70 enrolled7 locationsNCT07075185
Recruiting
Phase 1
TriPRIL CAR T Cells in Multiple Myeloma
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Marcela V. Maus, M.D.,Ph.D.18 enrolled1 locationNCT05020444
Recruiting
Phase 1
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Multiple Myeloma in RelapseRefractory Multiple MyelomaPlasmacytoid; Lymphoma
iCell Gene Therapeutics12 enrolled2 locationsNCT04162353
Recruiting
Phase 1
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
NeoplasmsMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
Technische Universität Dresden16 enrolled1 locationNCT05836896
Recruiting
Phase 1Phase 2
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+1 more
Essen Biotech60 enrolled1 locationNCT07032129
Recruiting
Phase 1Phase 2
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma
Multiple MyelomaMultiple Myeloma in Relapse
Universitätsklinikum Hamburg-Eppendorf45 enrolled5 locationsNCT05853965
Recruiting
Phase 1Phase 2
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Chongqing Precision Biotech Co., Ltd80 enrolled1 locationNCT04271644
Recruiting
Phase 1Phase 2
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Chongqing Precision Biotech Co., Ltd80 enrolled1 locationNCT04776330
Recruiting
Phase 1
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics30 enrolled1 locationNCT06225310
Recruiting
Phase 1
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Luminary Therapeutics30 enrolled1 locationNCT05546723
Recruiting
Phase 1Phase 2
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma in Relapse
Shenzhen University General Hospital10 enrolled1 locationNCT06644443